Clinical Trial Update: A Real-world Study on Golidocitinib-based Therapeutic Regimens for the Treatment of Patients With Peripheral T-cell Lymphoma

View source ↗

Summary

A real-world study evaluating regimens based on golidocitinib for peripheral T-cell lymphoma is not yet recruiting, sponsored by Ruijin Hospital.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Golidocitinib (golidocitinib)

Snippet

Sponsor: Ruijin Hospital | Conditions: Peripheral T-cell Lymphoma (PTCL) | Status: NOT_YET_RECRUITING